Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Author

CHEN, G¹ ; FENG, J² ; LU, S⁹ ; ZHANG, L¹⁰ ; HU, C.-P¹¹ ; HU, C¹² ; LUO, Y¹³ ; CHEN, L¹⁴ ; YE, M¹⁵ ; HUANG, J¹⁶ ; ZHI, X¹⁷ ; ZHANG, Y¹⁸ ; ZHOU, C³ ; XIU, Q¹⁹ ; MA, J²⁰ ; ZHANG, L²¹ ; YOU, C²² ; WU, Y.-L⁴ ; LIU, X.-Q⁵ ; WANG, C⁶ ; ZHANG, S⁷ ; WANG, J⁸ ; ZHOU, S³ ; REN, S³
[1] Tumor Medicine, The Cancer Hospital of Harbin Medical University, Harbin, India
[2] Medical Oncology, Jiangsu Province Cancer Hospital, Nanjing, India
[3] Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, India
[4] Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, India
[5] Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Cancer Center, Beijing, India
[6] Department of Medical Oncology, Tianjin Cancer Hospital, Tianjin, India
[7] Beijing Chest Hospital, Capital Medical University, Beijing, India
[8] Peking University School of Oncology, Beijing Cancer Hospital, Beijing, India
[9] Shanghai Chest Hospital, affiliated to Shanghai Jiao Tong University, Shanghai, India
[10] Sun Yat-sen University Cancer Center, Guangzhou, India
[11] Xiangya Hospital, India
[12] Second Xiangya Hospital, Central South University, , Changsha, India
[13] Hunan Province Cancer Hospital, Changsha, India
[14] Cancer Hospital Shantou University Medical College, Shantou, India
[15] Renji Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, India
[16] The First Affiliated Hospital of Suzhou University, Suzhou, India
[17] Thoracic Surgery Department, Xuanwu Hospital of Capital Medical University, Beijing, India
[18] Zhejiang Cancer Hospital, Hangzhou, India
[19] Changzhen Hospital, The Second Military Medical University, Shanghai, India
[20] Harbin Institute of Hematology and Oncology, Harbin, India
[21] Peking Union Medical College Hospital, Beijing, India
[22] Nanfang Hospital, Southern Medical University, Guangzhou, China

Source

Annals of oncology. 2013, Vol 24, Num 6, pp 1615-1622, 8 p ; ref : 19 ref

ISSN

0923-7534

Scientific domain

Medical oncology; Pharmacology drugs

Publisher

Oxford University Press, Oxford

Publication country

United Kingdom

Document type

Article

Language

English

Author keyword

EGFR mutations chemotherapy erlotinib non-small-cell lung cancer (NSCLC) quality of life (QoL)

Keyword (fr)

Analyse Anticancéreux Cancer du poumon Carcinome non petite cellule bronchopulmonaire Chimiothérapie Erlotinib Etude comparative Génétique Homme Malade Mutation Qualité de vie Randomisation Récepteur facteur croissance épiderme Stade avancé Traitement de première intention Anti-EGFR Inhibiteur de la tyrosine kinase de l'EGFR Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Traitement Transferases Tumeur maligne

Keyword (en)

Analysis Antineoplastic agent Lung cancer non-small cell lung carcinoma Chemotherapy Erlotinib Comparative study Genetics Human Patient Mutation Quality of life Randomization Epidermal growth factor receptor Advanced stage First line treatment Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Treatment Transferases Malignant tumor

Keyword (es)

Análisis Anticanceroso Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Quimioterapia Erlotinib Estudio comparativo Genética Hombre Enfermo Mutación Calidad vida Aleatorización Receptor del factor de crecimiento epidérmico Estadio avanzado Tratamiento de primera línea Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Tratamiento Transferases Tumor maligno

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum

Discipline

Pharmacological treatments Pulmonology Tumours

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

27427237

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS